IRI IEMR Resources Inc

IRI Separation Technologies Inc. (TSX VENTURE:IRI) (the "Company") is pleased to
announce that it has closed the second and final tranche of the amended private
placement that was disclosed in news releases dated July 27, 2007 and August 9,
2007. The Company has issued a further 87,000 units at a price of $0.35 per unit
(a "Unit"), and received additional gross proceeds of $30,450. Each Unit
consists of one common share and one warrant, entitling the holder to purchase
one common share for 24 months at $0.45 per share. The Company did not pay any
finders fees in connection with the sale of the additional Units.


The proceeds from the sale of the Units will be used for general working capital
and to purchase additional equipment to increase antibody production. All
securities are subject to a four month hold period commencing from the date of
closing.


About IRI Separation Technologies Inc.

IRI Separation Technologies Inc. (TSX VENTURE:IRI) is a biotechnology company
that specializes in the extraction, development and commercialization of
monoclonal and polyclonal immunoglobulin antibodies for virus and bacteria
related health issues. Intended for use as a nutraceutical for human
consumption, the antibodies are derived from bovine whey or chicken eggs. The
immunoglobulin antibodies are intended for both the general and specific
antibody market.


On behalf of the Board of Directors,

John Mason, President and CEO

IEMR Resources (TSXV:IRI)
Historical Stock Chart
From Jun 2024 to Jul 2024

IEMR Resources (TSXV:IRI)
Historical Stock Chart
From Jul 2023 to Jul 2024